Erectile dysfunction: A present day coronary disease risk equivalent.

about

Erectile dysfunction: A present day coronary disease risk equivalent.

Item

http://www.wikidata.org/entity/Q42320427

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Erectile dysfunction: A present day coronary disease risk equivalent.

@en

Erectile dysfunction: A present day coronary disease risk equivalent.

@nl

type

Item

label

Erectile dysfunction: A present day coronary disease risk equivalent.

@en

Erectile dysfunction: A present day coronary disease risk equivalent.

@nl

prefLabel

Erectile dysfunction: A present day coronary disease risk equivalent.

@en

Erectile dysfunction: A present day coronary disease risk equivalent.

@nl

P1476

Erectile dysfunction: A present day coronary disease risk equivalent.

@en

P2093

Aditya Kapoor

http://www.w3.org/2001/XMLSchema#string

Rohit Kapoor

http://www.w3.org/2001/XMLSchema#string

P2860

Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease?

Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel.

Erectile dysfunction and risk of cardiovascular disease: meta-analysis of prospective cohort studies.

The worldwide prevalence and epidemiology of erectile dysfunction.

Clinical trials of sildenafil citrate (Viagra) demonstrate no increase in risk of myocardial infarction and cardiovascular death compared with placebo.

Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).

A population-based, longitudinal study of erectile dysfunction and future coronary artery disease.

Erectile dysfunction and coronary artery disease prediction: evidence-based guidance and consensus.

The effect of statins on erectile dysfunction: a meta-analysis of randomized trials.

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE i

P304

307-310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.4103/0971-5916.198669

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

144

http://www.w3.org/2001/XMLSchema#string

P577

2016-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28139526

http://www.w3.org/2001/XMLSchema#string

P932

5320833

http://www.w3.org/2001/XMLSchema#string